Literature DB >> 29683912

ACOG Technology Assessment No. 13: Hysteroscopy.

.   

Abstract

Hysteroscopy is performed to view and treat pathology within the uterine cavity and endocervix. Diagnostic hysteroscopy allows visualization of the endocervical canal, endometrial cavity, and fallopian tube ostia. Operative hysteroscopy incorporates the use of mechanical, electrosurgical, or laser instruments to treat intracavitary pathology and perform hysteroscopic sterilization procedures. Selection of a distending medium requires consideration of the advantages, disadvantages, and risks associated with various media as well as their compatibility with electrosurgical or laser energy. A preoperative consultation allows the patient and physician to discuss the hysteroscopic procedure, weigh its inherent risks and benefits, review the patient's medical history for any comorbid conditions, and exclude pregnancy. Known pregnancy, genital tract infections, and active herpetic infection are contraindications to hysteroscopy. The most common perioperative complications associated with operative hysteroscopy are hemorrhage, uterine perforation, and cervical laceration. The procedure is minimally invasive and can be used with a high degree of safety.

Entities:  

Mesh:

Year:  2018        PMID: 29683912     DOI: 10.1097/AOG.0000000000002634

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  The Impact of Hysteroscopic Tissue Removal Systems on Histopathologic Analysis for Benign and Cancerous Endometrial Pathology: An Ex Vivo Study.

Authors:  Steven R Lindheim; Kimberly Lincenberg; Michelle A Wood; Emily Kemner; Megan K Burns; Daniel L Hood; Rose Maxwell; Miryoung Lee
Journal:  J Obstet Gynaecol India       Date:  2018-09-11

2.  Deep learning model for classifying endometrial lesions.

Authors:  YunZheng Zhang; ZiHao Wang; Jin Zhang; CuiCui Wang; YuShan Wang; Hao Chen; LuHe Shan; JiaNing Huo; JiaHui Gu; Xiaoxin Ma
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.